Search

Your search keyword '"Zhang, Huilai"' showing total 787 results

Search Constraints

Start Over You searched for: Author "Zhang, Huilai" Remove constraint Author: "Zhang, Huilai"
787 results on '"Zhang, Huilai"'

Search Results

1. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE

5. Nonreciprocal slow or fast light in anti-$\mathcal{PT}$-symmetric optomechanics

6. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

8. Research Progress on Molecular Diagnosis and Individualized Treatment for Malignant Lymphoma

10. Anti-$\mathcal{PT}$-symmetric Kerr gyroscope

12. China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)

13. First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study

14. Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

15. Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study

16. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

20. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

21. Breaking Anti-$\mathcal{PT}$ Symmetry by Spinning a Resonator

22. Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

23. ADAR1-mediated RNA editing promotes B cell lymphomagenesis

25. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

31. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China

32. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma

34. A retrospective analysis of mature T- and NK-cell lymphomas

35. Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma

36. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia

38. Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

39. Chlorantraniliprole Enhances Cellular Immunity in Larvae of Spodoptera frugiperda (Smith) (Lepidoptera: Noctuidae).

40. Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes.

42. Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

43. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis

45. Upregulation of tumor suppressor PIAS3 by Honokiol promotes tumor cell apoptosis via selective inhibition of STAT3 tyrosine 705 phosphorylation

46. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

48. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Catalog

Books, media, physical & digital resources